FDA panel supports approval of Boehringer's olodaterol for COPD

An FDA advisory panel endorsed the approval of Boehringer Ingelheim's olodaterol as a once-daily bronchodilator treatment for chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Boehringer plans to market the drug in a soft mist inhaler under the name Striverdi Respimat.

View Full Article in:

Bloomberg Businessweek · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA